Advertisement

Digestive Diseases and Sciences

, Volume 42, Issue 4, pp 817–822 | Cite as

Fecal β-D-Galactosidase Production and Bifidobacteria Are Decreased in Crohn's Disease

  • C. Favier
  • C. Neut
  • C. Mizon
  • A. Cortot
  • J. F. Colombel
  • J. Mizon
Article

Abstract

Digestive bacterial microflora play a major rolein the pathogenesis of Crohn's disease (CD). Bacterialenzyme activities, especially β-D-galactosidase,are decreased in fecal extracts from CD patients. We hypothesized that an alteration of thecolonic flora might be responsible for this decrease.Indeed, we demonstrate that β-D-galactosidaseproduction in supernates of anaerobic cultures wassignificantly (P < 0.01) reduced in feces from patientswith active Crohn's disease (N = 7), when compared tohealthy controls (N = 8). Therefore using X-gal andselective media, we enumerated bacteria able to releaseβ-D-galactosidase in feces from patients with active (N = 16) orquiescent disease (N = 5) and healthy controls (N = 14).Bifidobacteria numbers were significantly reduced inpatients (P < 0.01 for active; P < 0.02 forquiescent disease) whereas Bacteroides and Lactobacilli countsremained unchanged. β-D-Galactosidase activity andBifidobacteria counts were significantly correlated (P< 0.03). Bifidobacteria are regarded as beneficial for the host. The reduction in Bifidobacteriais responsible for decreased β-D-galactosidaseactivity. Thus oral administration of prebiotics thatpromote their growth might have potential therapeutic interest.

CROHN'S DISEASE BIFIDOBACTERIA β-D-GALACTOSIDASE 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Sartor RB: The role of normal enteric bacteria and bacterial products in chronic intestinal inflammation. In Inflammatory Bowel Disease. GNJ Tygtat, JFW Bartelsman, SJH van Deventer (eds). Dordrecht, Kluwer Academic Publishers, 1995, pp 519–527Google Scholar
  2. 2.
    Gorbach SL, Nahas L, Plaut AG, Weinstein L, Patterson JF, Levitan R: Studies of intestinal microflora. Gastroenterology 54:575–587, 1968Google Scholar
  3. 3.
    West B, Lendrum R, Hill MJ, Walker G: Effects of sulfasalazine (Salazopyrin) on fecal flora in patients with inflammatory bowel disease. Gut 15:960–965, 1974Google Scholar
  4. 4.
    Keighley MRB, Arabi Y, Dimock F, Burdon DW, Allan RN, Alexander-Williams J: Influence of inflammatory bowel disease on intestinal microflora. Gut 19:1099–1104, 1978Google Scholar
  5. 5.
    Krook A, Danielsson D, Kjellander J, Jarnerot G: The effect of metronidazole and sulfasalazine on the fecal flora in patients with Crohn's disease. Scand J Gastroenterol 16:183–192, 1981Google Scholar
  6. 6.
    Wensinck F, Custers-van Lieshout LMC, Poppelaars-Kustermans PAJ, Schröder AM: The fecal flora of patients with Crohn's disease. J Hyg Camb 87:1–12, 1981Google Scholar
  7. 7.
    Ruseler-van Embden JGH, Both Patoir HC: Anaerobic gramnegative fecal flora in patients with Crohn's disease and healthy subjects. Antonie van Leeuwenhoek 49:125–132, 1983Google Scholar
  8. 8.
    Hudson MJ, Hill MJ, Elliot PR, Berghouse LM, Burnham WR, Lennard-Jones JE: The microbial flora of the rectal mucosa and feces of patients with Crohn's disease before and during antimicrobial chemotherapy. J Med Microbiol 18:335–345, 1984Google Scholar
  9. 9.
    Van de Merwe JP, Schröder AM, Wensinck F, Hazenberg MP: The obligate anaerobic fecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol 23:1125–1131, 1988Google Scholar
  10. 10.
    Giaffer MH, Holdsworth CD, Duerden BI: The assessment of fecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 35:238–243, 1991Google Scholar
  11. 11.
    Gilberts ECAM, Greenstein AJ, Katsel P, Harpaz N, Greenstein RJ: Molecular evidence for two forms of Crohn disease. Proc Natl Acad Sci USA 91:12721–12724, 1994Google Scholar
  12. 12.
    Rhodes JM, Gallimore R, Elias E, Allan RN, Kennedy JF: Fecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease. Gut 26:761–765, 1985Google Scholar
  13. 13.
    Leijonmarck CE, Bergstrand LO, Carlstedt-Duke B, Gustafsson A, Midtvedt AC, Norin KE, Saxerholt H, Midtvedt T: Total parenteral nutrition and the function of the intestinal microflora in Crohn's disease. Scand J Gastroenterol 23:59–64, 1988Google Scholar
  14. 14.
    Ruseler-van Embden JGH, van Lieshout LMC: Increased fecal glycosidases in patients with Crohn's disease. Digestion 37:43–50, 1987Google Scholar
  15. 15.
    El Yamani J, Mizon C, Capon C, Colombel JF, Fournet B, Cortot A, Mizon J: Decreased fecal exoglycosidase activities identify a subset of patients with active Crohn's disease. Clin Sci 83:409–415, 1992Google Scholar
  16. 16.
    Carrette O, Favier C, Mizon C, Neut C, Cortot A, Colombel JF, Mizon J: The bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci 40:2641–2646, 1995Google Scholar
  17. 17.
    Canva Delcambre V, Soenen V, Mizon C, Cortot A, Mizon J, Colombel JF: L'activite β-D-galactosidasique fecale est diminúee au cours de la maladie de Crohn. Gastroenterol Clin Biol 17:718–722, 1993Google Scholar
  18. 18.
    Best WR, Beckel JM, Singleton JW, Kern F Jr: Development of Crohn's disease activity index. Gastroenterology 70:439–444, 1976Google Scholar
  19. 19.
    Favier C, Neut C, Mizon C, Cortot A, Colombel JF, Mizon J: Research and identification of human fecal anaerobic bacteria producing β-D-galactosidase: A new methodology. J Microbiol Methods 27:25–31, 1996Google Scholar
  20. 20.
    Beerens H: An elective and selective isolation medium for Bifidobacterium spp. Lett Appl Microbiol 11:155–157, 1990Google Scholar
  21. 21.
    Livingston SJ, Kominos SD, Lee RB: New medium for selection and presumptive identification of the Bacteroides fragilis group. J Clin Microbiol 7:448–453, 1978Google Scholar
  22. 22.
    MacFarlane GT, Hay S, Gibson GR: Influence of mucin on glycosidase, protease and arylamidase activities of human gut bacteria grown in a 3-stage continuous culture system. J Appl Bacteriol 66:407–417, 1989Google Scholar
  23. 23.
    Ikeda N, Saito Y, Shimizu J, Ochi A, Mizutani J, Watabe J: Variations in concentrations of bacterial metabolites, enzyme activities, moisture, pH and bacterial composition between and within individuals in feces of seven healthy adults. J Appl Bacteriol 77:185–194, 1994Google Scholar
  24. 24.
    Gibson GR, Wang X: Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 77:412–420, 1994Google Scholar
  25. 25.
    Gibson GR, Roberfroid MB: Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr 125:1401–1412, 1995Google Scholar
  26. 26.
    Liao W, Cui XS, Jin XY, Floŕen CH: Lactulose—a potential drug for the treatment of inflammatory bowel disease. Med Hypoth 43:234–238, 1994Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • C. Favier
  • C. Neut
  • C. Mizon
  • A. Cortot
  • J. F. Colombel
  • J. Mizon

There are no affiliations available

Personalised recommendations